| Project/Area Number |
07407042
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (A)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Orthopaedic surgery
|
|---|
| Research Institution | Sapporo Medical university |
|---|
Principal Investigator |
ISHII Seiichi Sapporo Medical university, Professor, 医学部, 教授 (20001000)
|
|---|
| Project Period (FY) |
1995 – 1998
|
| Project Status |
Completed (Fiscal Year 1998)
|
| Budget Amount *help |
¥35,400,000 (Direct Cost: ¥35,400,000)
Fiscal Year 1998: ¥6,400,000 (Direct Cost: ¥6,400,000)
Fiscal Year 1997: ¥5,400,000 (Direct Cost: ¥5,400,000)
Fiscal Year 1996: ¥11,600,000 (Direct Cost: ¥11,600,000)
Fiscal Year 1995: ¥12,000,000 (Direct Cost: ¥12,000,000)
|
|---|
| Keywords | osteosarcoma / Erb B receptor family / ets oncogene family / MMP-9 / activation induced cell death / lymphokine activated killer cell / N-acetyl cysteine / lymphokine activated killer cell / F344ラット由来骨肉腫 / LM8マウス由来骨肉腫 / 接着分子導入細胞ワクチン / B-7ファミリー / 細胞外マトリックス分解酵素 / etsがん遺伝子ファミリー / SK-BR-3乳癌細胞株 / etsがん遺伝子 / C57BL / 6マウス線維肉腫 / ヒト胎児頭蓋由来骨芽細胞 / 接着分子 / ヒト骨内シアル酸含有蛋白 / 骨肉腫細胞株 / ヒートショック蛋白hsp90 / 抗腫瘍ワクチン / 分子生物学 |
|---|
| Research Abstract |
Research results are summarized as follows.
1. Establishment of an in vitro experimental system for evaluation of role of dexamethasone, extracellular matrix proteins, and TGF-beta in regulation of osteoblastic differentiation, using anewly developed human osteoblastic cell line, SV-HFO.
2. Detection of bone sialoprotein in bone-derived malignancies using newly developed monoclonal antibodies.
3. Experimental therapy of osteosarcoma with a combination of a chemotherapeutic reagent, MTX, and B7-transfected tumor vaccine in a rat orthotopic implantation model.
4. Demonstration of an inhibitory role of hsp9O in regulation of growth of a human osteosarcoma cell line, BOS.
5. Induction of MMP-9 and high metastatic phenotype in lines of human and mouse malignant tumor cells by transfection of ElAF, a member of eta oncogene fanily.
6. Demonstration of presence of concomitant tumor resistance, an inhibitory effect of the primary lesion on metastatic tumor growth, in a rat orthotopic tumor implantation model of osteosarcoma.
7. Demonstration of correlation between lack of erbB2 expression and poor prognosis in osteosarcoma patients.
8. Augmentation of anti-tumor immunity by inhibition of AICD, activation-induced cell death, of lymphokine-activated killer cells by pretreatmen with N-acetyl cysteine.
|
